rs12721629 — CYP3A4 *16B

CYP3A4*16B — A Rare East Asian Variant Altering Drug Metabolism in a Substrate-Dependent Way

CYP3A4 is the most abundant drug-metabolizing enzyme in the human liver, responsible for the biotransformation of approximately 50% of all clinically used medications¹¹ 50% of all clinically used medications
Including statins, immunosuppressants, calcium channel blockers, benzodiazepines, chemotherapy agents, and many antibiotics. The CYP3A4*16B haplotype, defined primarily by the rs12721629 variant, carries a missense substitution (Thr185Ser in older literature numbering; p.Leu373Val in current HGVS notation using transcript NM_017460.6) that alters the enzyme's active site geometry in a way that affects different drug substrates to different degrees.

This variant is largely confined to Japanese and broader East Asian populations, where heterozygous carriers appear in roughly 3-4% of individuals. In European, African, and South Asian populations it is essentially absent. The CYP3A4 gene itself sits on the minus strand of chromosome 7, so the coding-strand change (c.554C>G in older transcript notation, c.1117C>G in NM_017460.6) is reported on the plus strand as G>C at chromosomal position 99,762,177 (GRCh38).

The Mechanism

The Thr185Ser substitution (threonine-to-serine at position 185 in the older protein numbering) changes a hydroxyl-bearing residue in the substrate-binding channel of CYP3A4. In vitro studies using recombinant enzyme²² In vitro studies using recombinant enzyme
CYP3A4*16 expressed in Sf21 insect cells co-expressing human NADPH-P450 reductase revealed that the effect is strikingly substrate-dependent: intrinsic clearance of midazolam (a standard CYP3A4 probe) fell by about 50% for the primary 1'-hydroxylation pathway and 30% for 4-hydroxylation, while carbamazepine epoxidation dropped by 74%. This contrast with, for example, CYP3A4*22, which reduces enzyme expression uniformly across substrates, suggests the *16B substitution changes the substrate access channel geometry rather than overall protein stability or expression.

The kinetic mechanism differs by substrate. For midazolam, the variant shows elevated Km (reduced binding affinity) with lower Vmax. For carbamazepine, the changes are more complex and consistent with a distorted two-site cooperative binding model, suggesting the variant may disrupt allosteric activation normally seen with this substrate.

The Evidence

The most clinically informative data comes from two studies in Japanese cancer patients. Sai et al. examined 235 patients³³ Sai et al. examined 235 patients
paclitaxel pharmacokinetics measured in 229 with usable plasma samples receiving paclitaxel chemotherapy and identified eight *16B carriers (all heterozygotes). Carriers showed a 20% lower median AUC ratio for the 3'-p-hydroxylation metabolite and a 2.4-fold higher ratio for the 6α-hydroxylation product (P<0.001), indicating that CYP3A4*16B shifts paclitaxel metabolism away from the 3'-p-hydroxylation route toward the 6α-hydroxylation route — with potential consequences for drug efficacy and metabolite toxicity profiles.

Sai et al. studied 177 Japanese cancer patients⁴⁴ Sai et al. studied 177 Japanese cancer patients
Irinotecan pharmacokinetics with CYP3A4 haplotype analysis receiving irinotecan and found that male patients carrying *16B had approximately 50% lower APC/irinotecan ratios, indicating significantly reduced CYP3A4-mediated oxidative metabolism of this anticancer drug. No female *16B carriers were enrolled. Although overall irinotecan total clearance was not significantly different between genotypes — suggesting compensatory pathways — the altered metabolite ratios could affect the balance between efficacy and toxicity (the APC pathway is thought to be a detoxification route).

Maekawa et al.⁵⁵ Maekawa et al.
Kinetic characterization of CYP3A4.16 in insect cell microsomes provided the mechanistic foundation: recombinant CYP3A4*16 shows 50% reduced intrinsic clearance for midazolam 1'-hydroxylation, 30% for midazolam 4-hydroxylation, and 74% for carbamazepine 10,11-epoxide formation, confirming that the magnitude of impairment varies considerably by substrate.

CYP3A4*16B is not included in current CPIC or DPWG clinical guidelines, which focus on CYP3A4*22 (rs35599367) and the CYP3A5 *1/*3 system (rs776746) as the established pharmacogenomic variants for CYP3A4 pathway guidance. The rarity of *16B outside East Asian populations limits the evidence base for formal guideline development.

Practical Actions

Because CYP3A4*16B is heterozygous in virtually all carriers and causes moderate, substrate-dependent activity reduction, the clinical impact depends heavily on which drugs you take. For chemotherapy drugs like paclitaxel and irinotecan, the altered metabolite ratios could affect both efficacy and the toxicity profile — oncologists should be aware that standard dosing may produce different metabolite distributions in *16B carriers. For drugs with narrow therapeutic windows (carbamazepine, tacrolimus), the 50-74% reduction in intrinsic clearance observed in vitro suggests that doses appropriate for normal CYP3A4 metabolizers may need adjustment.

The absence of CYP3A4*16B from clinical pharmacogenomic panels used in Western countries means carriers are unlikely to receive a pharmacogenomic alert for this specific variant. East Asian patients undergoing comprehensive pharmacogenomic testing may benefit from inclusion of this variant.

Interactions

CYP3A4*16B's effects are additive with other reduced-function CYP3A variants. Individuals of East Asian ancestry who carry both CYP3A4*16B and CYP3A5*3/*3 (rs776746 CC, the most common genotype globally) would have reduced function in both CYP3A enzymes, potentially reaching total CYP3A activity levels comparable to carriers of CYP3A4*22 in European populations.

The substrate-dependent nature of *16B also means that drug-drug interactions can produce unpredictable results. A CYP3A4 inhibitor like itraconazole that uniformly blocks enzyme activity may have a larger relative impact on carbamazepine (already 74% reduced) than on midazolam (50% reduced) in *16B carriers, since both baseline activities start from a lower point. Conversely, inducers like rifampin may partially rescue activity in *16B by upregulating enzyme expression to compensate for per-molecule inefficiency.

The CYP3A4*22 variant (rs35599367) is a separate, more common, and better-studied reduced-function allele that should be tested alongside *16B in East Asian patients receiving narrow therapeutic index CYP3A4 substrates.